Patheon-2Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville (NC, USA) manufacturing site.

The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suite that are compliant with regulatory authorities. The PDS Suites 1 and 2 provide 7000-square-feet in GMP steriles manufacturing space.

The newly built PDS suite will manufacture sterile liquid and lyophilised drug products. It features freeze dryers and a fully integrated filling line fitted with a Restricted Access Barrier System (RABS) for sterile drug products.

The company has made the investment in disposable manufacturing in this suite eliminating the need for cleaning verification for liquid filling, reducing set up time/product losses and enhancing sterility assurance.

This suite is highly sophisticated, fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes via Patheon’s network of commercial scale capabilities either co-existing within the Greenville facility, or in Europe.

“As the industry continues to innovate, customers will require even more advanced solutions, integrating development and commercial service, to meet their business needs,” said Franco Negron, President of Patheon’s drug product and pharmaceutical development services for North America.

“The increasing focus on pharma to reduce costs will lead forward-thinking companies to capitalize on their core competencies – focusing on what they do best, while strategically partnering with companies such as Patheon to deliver the expertise, customised solutions and technical capabilities to support the production of their small and large molecule products.”

Patheon’s Greenville manufacturing site is a large multipurpose pharmaceutical manufacturing and packaging campus. The facility provides both solid dose form manufacturing/packaging and sterile dose manufacturing, filling and lyophilisation of both biopharmaceuticals and small molecules.

Another exciting development in Greenville, NC is the installation of a state-of-the-art continuous manufacturing suite.